AgendaFriday, December 6, 2024

7:00 AM - 8:00 AM

Registration and Breakfast/Coffee Talk with Key Opinion Leaders

In-person learners are invited to start off the morning with Key Opinion Leaders as well as other colleagues to enjoy coffee and informal discussions about a hot topic related to mood disorders.

8:00 AM - 8:10 AM

Opening Remarks by Moderator

Presented by Lisa Harding, MD

8:10 AM - 9:10 AM

Keynote Session: Do Obesity and Diabetes Mellitus Metastasize to the Brain? "Metaboptosis" and Implications for Potential Therapeutics in Psychiatry

Presented by Roger S. McIntyre, MD, FRCPC

In this compelling session, we will explore the medical interface of GLP-1 agonists with psychiatric disorders including the neurobiological overlap of medical disorders and psychiatric disorders and the potential for therapeutic overlap focusing on anti-inflammatories and novel anti-diabetic agents as psychiatric treatments. Once we understand the role of GLP in normal brain function, we will discuss the role of metabolism in the pathology, phenomenology and comorbidity of psychiatric disorders and dive into the data supporting the targeting of metabolic proteins, including GLP, as possibly innovative, mechanistically informed treatment options in psychiatry.

9:10 AM - 9:20 AM

Break

9:20 AM - 10:20 AM

Non-CME Educational Session

Managed by MDOutlook / Clinical Care Solutions, a CEA Company

10:20 AM - 10:30 AM

Break

10:30 AM - 11:30 AM

Estrogen and Mood: Psychiatric Considerations Over the Reproductive Lifecycle

Presented by Jennifer L. Payne, MD

Dramatic hormonal changes surrounding reproductive life events such as menarche, pregnancy, and menopause are normal, yet only some women experience significant impact of these fluctuations on mood. This session explores the relationship between brain estrogen sensitivity and depression, including correlation of epigenetic biomarkers with clinical symptomatology.

11:30 AM - 12:30 PM

Agitation, Psychosis, Behavioral Challenges in Alzheimer’s Disease

Presented by Anton P. Porsteinsson, MD

This presentation will describe the phenomenology, neurobiological mechanisms, and management of neuropsychiatric symptoms in Alzheimer's disease and other dementias, including agitation, psychosis, mood changes, and apathy. Overall management approaches, findings from treatment trials, and novel approaches in development will be discussed.

12:30 PM - 1:00 PM

Break & Lunch for in-person attendees

1:00 PM - 2:00 PM

Non-CME Educational Session

Managed by MDOutlook / Clinical Care Solutions, a CEA Company

2:00 PM - 2:10 PM

Break

2:10 PM - 3:40 PM

Innovation Insight: How are Novel Agents Reshaping Schizophrenia's Landscape?

Presented by John M. Kane, MD

In this session, participants will review the mechanism of disease of schizophrenia and hear about the potential impact of novel agents in changing the landscape of schizophrenia treatment in addressing symptom domains and adverse event profiles.

3:50 PM - 4:50 PM

Navigating Cannabis Use in Psychiatric Populations: Drug-Drug Interactions and Other Pharmacologic Considerations

Presented by  John S. Markowitz, PharmD, BCPP

Increasing use of medical and recreational cannabis can lead to safety concerns if clinicians and patients are not aware of potential interactions with other medications. This session will cover potential cannabis-related drug-drug interaction concerns that may arise in psychiatric populations and present strategies for patient communication and education.

4:50 PM - 5:00 PM

Closing Remarks by Moderator

Presented by Lisa Harding, MD

5:00 PM - 6:30 PM

Welcome Reception

In-person learners are invited to join us at the welcome reception, Friday evening after the first day of the conference. Connect with familiar colleagues, network with new faces, and spark meaningful conversation over food, music, and fun in this atmosphere of intellectual curiosity!